On Tuesday, Shares of Southwestern Energy Company (NYSE:SWN), subtract -1.16% and shut at $11.06 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $10.80 and $11.36. Southwestern Energy Company, an independent natural gas and oil company, explores for, develops, and produces natural gas and oil mainly in the United States. It operates through two segments, Exploration and Production and Midstream Services. The company focuses on the Marcellus Shale, an unconventional natural gas reservoir covering about 270,335 net acres in northeast Pennsylvania; and the Fayetteville Shale, an unconventional natural gas reservoir covering about 957,641 net acres in Arkansas. It also engages in the exploration and production activities in Colorado and Louisiana. In addition, the company is involved in gathering, marketing, and transporting natural gas, and oil and natural gas liquids. As of December 31, 2015, it had a pipeline of 2,044 miles in Arkansas and 16 miles in Louisiana in its gathering systems.
Shares of AstraZeneca plc (ADR) (NYSE:AZN), subtract -3.33% and shut at $26.43 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $26.38 and $27.16. The association’s commercial center capitalization is $65.82 Billion with the general uncommon loads of 1.26 billion. Results from the international, multicenter ChildHood Asthma Safety and Efficacy (CHASE) 3 Phase III study showed that SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms significantly improved lung function in pediatric patients between 6 to <12 years of age with asthma as compared to budesonide 80 micrograms, demonstrating its appropriateness as step-up therapy in this patient population.
The CHASE 3 Phase III study evaluated the efficacy and safety of budesonide/formoterol in a pressurized metered dose inhaler (pMDI) 80/2.25 micrograms, and SYMBICORT pMDI 80/4.5 micrograms, contrast with budesonide pMDI 80 micrograms in children with asthma, ages 6 to <12 years, who were given two inhalations twice a day for 12 weeks. The children had formerly received either medium-dose inhaled corticosteroid (ICS) or ICS/ long-acting beta2-adrenergic agonists (LABA). The primary efficacy endpoint was change from baseline pre-dose (randomization) to 1-hour post-dose forced expiratory volume in one second (FEV1) at week 12.